Advertisement
Advertisement
Piptam

Piptam Indications/Uses

piperacillin + tazobactam

Manufacturer:

Siam Bheasach

Distributor:

Siam Pharmaceutical

Marketer:

Siam Pharmaceutical
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Indications/Uses
PIPTAM 4.5 G INJECTION is indicated for the treatment of the following systemic and/or local bacterial infections caused by susceptible organisms have been detected or are suspected: Lower respiratory tract infections; Complicated and uncomplicated urinary tract infections; Intra-abdominal infections; Skin and skin structure infections; Gynecological infections including postpartum endometritis and pelvic inflammatory disease (PID); Bacterial septicemia.
PIPTAM 4.5 G INJECTION is indicated for polymicrobial infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, lower respiratory tract).
PIPTAM 4.5 G INJECTION, in combination with an aminoglycoside, is indicated for the management of neutropenic adults or children.
In hospitalized children 2 to 12 years of age, PIPTAM 4.5 G INJECTION is indicated for treatment of Intra-abdominal infections (including appendicitis complicated by rupture or abscess, peritonitis and biliary infections). It has not been evaluated in this indication for pediatric patients below the age of 2 years.
Infections caused by Piperacillin susceptible organisms are also amenable to PIPTAM 4.5 G INJECTION treatment due to its Piperacillin content. Therefore, the treatment of mixed infections caused by both Piperacillin-susceptible organisms and β-lactamase-producing organisms susceptible to PIPTAM 4.5 G INJECTION should not require the addition of another antibiotic.
PIPTAM 4.5 G INJECTION is particularly useful in the treatment of mixed infections and in the empiric treatment prior to the availability of the results of sensitivity tests because of its broad spectrum of activity.
PIPTAM 4.5 G INJECTION acts synergistically with aminoglycosides against certain strains of Pseudomonas aeruginosa. Combined therapy has been successful, especially in patients with impaired host defences. Both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility test become available, antimicrobial therapy should be adjusted if necessary.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement